QUEST DIAGNOSTICS INCORPORATED MADISON, N.J., July 23, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that for the second quarter ended June 30, 2015, adjusted net income was $170 million compared to $157 million for 2014. Adjusted diluted EPS excluding amortization was $1.25 in the second quarter of 2015, compared to $1.19 in 2014. Amortization expense per diluted share was $0.08 in the second quarter of 2015 and $0.11 in 2014.
http://photos.prnewswire.com/prnvar/20150422/200883LOGO
For the second quarter of 2015, reported net income was $118 million, or $0.81 per diluted share, compared to $133 million, or $0.92 per diluted share, in 2014. Reported net income in the second quarter of 2015 was negatively impacted by charges of $52 million after tax, or $0.36 per diluted share, of which $41 million is associated with the company's recent debt refinancing. The remainder of the charges were related to restructuring and integration costs and ongoing efforts to drive operational excellence. In the second quarter of 2014, reported net income was reduced by charges of $24 million after tax, or $0.16 per diluted share, primarily related to restructuring and integration costs associated with acquisitions and ongoing efforts to drive operational excellence.
Second quarter 2015 revenue of $1.93 billion grew by 1.2% versus the prior year and grew 0.8% on an organic basis. Diagnostic information services revenue grew by 0.4%. Volume, measured by the number of requisitions, decreased by approximately 0.4%. Revenue per requisition grew by approximately 0.9%.
For the second quarter of 2015, adjusted operating income was $321 million, or 16.7% of revenues, compared to $296 million, or 15.5% of revenues, for 2014. Reported operating income was $301 million, or 15.6% of revenues, compared to $262 million, or 13.8% of revenues, in 2014. Adjusted cash provided by operations, reflecting cash charges for debt refinancing, was $324 million in the second quarter of 2015. Reported cash provided by operations in the second quarter of 2015 was $275 million and was negatively impacted by after tax cash charges of $49 million associated with the early retirement of debt in connection with the company's debt refinancing. In the second quarter of 2014, reported cash provided by operations was $280 million.
"In the second quarter we once again grew operating income faster than revenues, demonstrating results from our five-point strategy. We are not just driving growth, we are driving profitable growth," said Steve Rusckowski, President and Chief Executive Officer. "Our strategies to restore growth and drive operational excellence are delivering both a better customer experience and earnings growth. An important element of restoring growth is to engage with healthcare systems around their lab strategy. Our recently announced acquisition of MemorialCare Health System's outreach business is another great example of this effort. Also, we have updated our outlook to reflect the clinical trials joint venture, and have maintained our full year EPS guidance."
First Half Performance
Revenues were $3.76 billion for the first six months of 2015, 3.2% better than the prior year. Adjusted net income was $311 million for the first six months of 2015 compared to $279 million in 2014. Adjusted diluted EPS excluding amortization was $2.30 for the first six months of 2015, compared to $2.12 in 2014. Reported net income for the first six months of 2015 was $179 million, or $1.23 per diluted share, compared to $237 million, or $1.63 per diluted share, in 2014. Reported net income in 2015 was negatively impacted by charges of $132 million after tax, or $0.90 per diluted share, principally associated with the debt refinancing.
Adjusted operating income for the first six months of 2015 was $590 million, or 15.7% of revenues, compared to $532 million, or 14.6% of revenues, for 2014. On a reported basis, operating income was $529 million, or 14.1% of revenues, compared to $470 million, or 12.9% of revenues, in 2014. Adjusted cash provided by operations for the first six months of 2015 was $454 million. Reported cash provided by operations for the six months of 2015 was $327 million and was negatively impacted by after tax cash charges of $127 million associated with the company's debt refinancing. In the first six months of 2014, reported cash provided by operations was $364 million.
Outlook for 2015
For 2015, the company estimates results, before special items, as follows:
-- Full year 2015 revenue now expected to be between $7.49 billion and
$7.57 billion.
-- Revenue for 2014 on an equivalent basis excludes clinical trials
revenue reported in the third and fourth quarter of 2014 of $41
million and $46 million, respectively.
-- Updated 2015 revenue guidance is an increase of 2% to 3% versus 2014
on an equivalent revenue basis.
-- Previous 2015 revenue guidance was an increase of 2% to 3% versus
2014 reported revenue.
-- Adjusted diluted EPS excluding amortization to be between $4.70 and
$4.85, unchanged.
-- Adjusted cash provided by operations to exceed $850 million, versus
previous guidance that adjusted cash would approximate $850 million.
-- Capital expenditures to approximate $300 million, unchanged.
Note on Non-GAAP Financial Measures
As used in this press release: (i) for the purpose of income measures the term "adjusted" refers to operating performance measures that exclude special items such as charges on retirement of debt and related refinancing charges, restructuring and integration charges, and other items; (ii) the term "adjusted diluted EPS excluding amortization expense" represents the company's results before the impact of special items and amortization expense; (iii) the term "adjusted cash provided by operations" represents cash provided by operations before the cash impact of charges on retirement of debt; and (iv) the term "equivalent revenue" represents 2014 reported revenues excluding clinical trials revenues reported in the third and fourth quarters of 2014. Adjusted measures are presented because management believes those measures are useful adjuncts to reported results under accounting principles generally accepted in the United States. Adjusted measures should not be considered as an alternative to the corresponding measures determined under accounting principles generally accepted in the United States. The attached tables include reconciliations of adjusted measures to measures reported under accounting principles generally accepted in the United States.
Conference Call Information
Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The company suggests participants dial in approximately 10 minutes before the call. A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or by phone at 800-677-4302 for domestic callers or 402-998-0977 for international callers. Telephone replays will be available from approximately 10:30 a.m. Eastern Time today until midnight Eastern Time on August 21, 2015.
Anyone listening to the call is encouraged to read the company's periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.
About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.
The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.
This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com.
TABLES FOLLOW
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Operations
For the Three and Six Months Ended June 30, 2015 and 2014
(in millions, except per share data)
(unaudited)
Three Months Ended Six Months Ended
June 30, June 30,
-------- --------
2015 2014 2015 2014
---- ---- ---- ----
Net revenues $1,925 $1,902 $3,764 $3,648
Operating costs and expenses:
Cost of services 1,182 1,174 2,345 2,275
Selling, general and
administrative 429 440 848 855
Amortization of
intangible assets 20 25 41 47
Other operating (income)
expense, net (7) 1 1 1
--- --- --- ---
Total operating costs and
expenses 1,624 1,640 3,235 3,178
----- ----- ----- -----
Operating income 301 262 529 470
Other income (expense):
Interest expense, net (37) (42) (82) (81)
Equity in earnings of
equity method investees 7 6 14 12
Other (expense) income,
net (64) 3 (142) 4
Total non-operating
expenses, net (94) (33) (210) (65)
--- --- ---- ---
Income before income
taxes 207 229 319 405
Income tax expense 78 87 120 152
--- --- --- ---
Net income 129 142 199 253
Less: Net income
attributable to
noncontrolling interests 11 9 20 16
Net income attributable
to Quest Diagnostics $118 $133 $179 $237
---- ---- ---- ----
Earnings per share attributable to Quest
Diagnostics' common stockholders:
Basic $0.82 $0.92 $1.24 $1.64
----- ----- ----- -----
Diluted $0.81 $0.92 $1.23 $1.63
----- ----- ----- -----
Weighted average common shares
outstanding:
Basic 144 144 144 144
Diluted 145 145 145 145
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Balance Sheets
June 30, 2015 and December 31, 2014
(in millions, except per share data)
(unaudited)
June 30, December 31,
2015 2014
---- ----
Assets
------
Current assets:
Cash and cash
equivalents $150 $192
Accounts
receivable,
net 937 932
Inventories 109 110
Deferred
income taxes 161 169
Prepaid
expenses and
other
current
assets 173 200
Total current
assets 1,530 1,603
Property,
plant and
equipment,
net 906 933
Goodwill 5,987 6,032
Intangible
assets, net 1,022 1,071
Other assets 219 218
Non-current
assets held
for sale 56 -
--- ---
Total assets $9,720 $9,857
------ ------
Liabilities and
Stockholders' Equity
---------------------
Current liabilities:
Accounts
payable and
accrued
expenses $1,074 $1,191
Current
portion of
long-term
debt 168 518
Total current
liabilities 1,242 1,709
Long-term
debt 3,568 3,224
Other
liabilities 566 594
Stockholders' equity:
Quest Diagnostics
stockholders' equity:
Common stock,
par value 215 shares
$0.01 per issued at
share; 600 June 30,
shares 2015 and
authorized December 31,
at both June 2014,
30, 2015 and respectively
December 31,
2014; 216
shares and 2 2
Additional
paid-in
capital 2,444 2,418
Retained
earnings 5,793 5,723
Accumulated
other
comprehensive
loss (25) (27)
Treasury
stock, at
cost; 72
shares and
71 shares at
June 30,
2015 and
December 31,
2014,
respectively (3,900) (3,815)
------ ------
Total Quest
Diagnostics
stockholders'
equity 4,314 4,301
Noncontrolling
interests 30 29
--- ---
Total
stockholders'
equity 4,344 4,330
Total
liabilities
and
stockholders'
equity $9,720 $9,857
------ ------
Quest Diagnostics Incorporated and Subsidiaries
Consolidated Statements of Cash Flows
For the Six Months Ended June 30, 2015 and 2014
(in millions)
(unaudited)
Six Months Ended June 30,
-------------------------
2015 2014
---- ----
Cash flows from operating
activities:
Net income $199 $253
Adjustments to reconcile net
income to net cash provided
by operating activities:
Depreciation and
amortization 153 156
Provision for
doubtful
accounts 158 148
Deferred income
tax benefit (5) (26)
Stock-based
compensation
expense 27 25
Excess tax
benefits from
stock-based
compensation
arrangements (3) -
Other, net (5) (2)
Changes in operating assets
and liabilities:
Accounts
receivable (163) (191)
Accounts payable
and accrued
expenses (49) (39)
Income taxes
payable 17 44
Other assets and
liabilities,
net (2) (4)
Net cash
provided by
operating
activities 327 364
--- ---
Cash flows from investing
activities:
Business
acquisitions,
net of cash
acquired (6) (723)
Capital
expenditures (117) (117)
Increase in
investments and
other assets - (1)
Net cash used in
investing
activities (123) (841)
---- ----
Cash flows from financing
activities:
Proceeds from
borrowings 1,829 1,738
Repayments of
debt (1,821) (1,159)
Purchases of
treasury stock (149) (57)
Exercise of
stock options 55 30
Excess tax
benefits from
stock-based
compensation
arrangements 3 -
Dividends paid (103) (91)
Distributions to
noncontrolling
interests (19) (14)
Other financing
activities, net (41) (13)
Net cash (used
in) provided by
financing
activities (246) 434
---- ---
Net change in
cash and cash
equivalents (42) (43)
Cash and cash
equivalents,
beginning of
period 192 187
Cash and cash
equivalents,
end of period $150 $144
---- ----
Cash paid during the period
for:
Interest $99 $82
Income taxes $109 $138
Notes to Financial Tables
1) The computation of basic and diluted earnings per common share is as follows:
Three Months Ended Six Months Ended
June 30, June 30,
-------- --------
2015 2014 2015 2014
---- ---- ---- ----
(in millions, except per share data)
Amounts attributable to Quest
Diagnostics' common stockholders:
Net income attributable
to Quest Diagnostics $118 $133 $179 $237
Less: earnings
allocated to
participating
securities 1 - 1 1
Earnings available to
Quest Diagnostics'
common stockholders -
basic and diluted $117 $133 $178 $236
---- ---- ---- ----
Weighted average common
shares outstanding -
basic 144 144 144 144
Effect of dilutive securities:
Stock options and
performance share
units 1 1 1 1
Weighted average common
shares outstanding -
diluted 145 145 145 145
--- --- --- ---
Earnings per share attributable to
Quest Diagnostics' common
stockholders:
Basic $0.82 $0.92 $1.24 $1.64
----- ----- ----- -----
Diluted $0.81 $0.92 $1.23 $1.63
----- ----- ----- -----
2) Adjusted amounts for operating
income and net income attributable
to Quest Diagnostics represent the
company's results before the
impact of special items, such as
the charges on retirement of debt
and related refinancing charges,
restructuring and integration
charges and other items. Adjusted
diluted EPS excluding amortization
expense represents the company's
results before the impact of
special items and amortization
expense. Adjusted cash provided
by operations represents cash
provided by operations before the
cash impact of charges on
retirement of debt. Adjusted
measures are presented because
management believes those measures
are useful adjuncts to reported
results under accounting
principles generally accepted in
the United States when comparing
results of operations from period
to period. Adjusted measures
should not be considered as an
alternative to the corresponding
measures determined under
accounting principles generally
accepted in the United States.
The following table reconciles
reported results to adjusted
results:
Three Months Ended Six Months Ended
June 30, June 30,
-------- --------
2015 2014 2015 2014
---- ---- ---- ----
(dollars in millions, except per share data)
Adjusted operating
income:
------------------
Operating income $301 $262 $529 $470
Restructuring and
integration charges
(a) 23 27 54 51
Other (b) (3) 7 7 11
Adjusted operating
income $321 $296 $590 $532
---- ---- ---- ----
Adjusted operating
income as a
percentage of net
revenues:
------------------
Operating income as
a percentage of net
revenues 15.6% 13.8% 14.1% 12.9%
Restructuring and
integration charges
(a) 1.2 1.4 1.4 1.4
Other (b) (0.1) 0.3 0.2 0.3
Adjusted operating
income as a
percentage of net
revenues 16.7% 15.5% 15.7% 14.6%
---- ---- ---- ----
Adjusted net income:
--------------------
Net income
attributable to
Quest Diagnostics $118 $133 $179 $237
Charges on
retirement of debt
and related
refinancing charges
(c) (d) 41 - 94 -
Restructuring and
integration charges
(d) 14 19 33 34
Other (d) (3) 5 5 8
Adjusted net income $170 $157 $311 $279
---- ---- ---- ----
Adjusted diluted EPS
excluding
amortization
expense:
--------------------
Diluted earnings per
common share $0.81 $0.92 $1.23 $1.63
Charges on
retirement of debt
and related
refinancing charges
(c) (d) 0.28 - 0.64 -
Restructuring and
integration charges
(a) (d) 0.10 0.13 0.22 0.24
Other (b) (d) (0.02) 0.03 0.04 0.05
Amortization expense
(e) 0.08 0.11 0.17 0.20
Adjusted diluted EPS
excluding
amortization
expense $1.25 $1.19 $2.30 $2.12
----- ----- ----- -----
Adjusted cash
provided by
operations:
-------------
Cash provided by
operations $275 $280 $327 $364
Cash charges on
retirement of debt
(f) 49 - 127 -
---
Adjusted cash
provided by
operations $324 $280 $454 $364
---- ---- ---- ----
(a) Represents costs primarily
associated with workforce
reductions and professional
fees incurred in connection
with further restructuring and
integrating our business. The
following table summarizes the
impact of restructuring and
integration charges on the
company's consolidated
statements of operations:
Three Months Ended Six Months Ended
June 30, June 30,
-------- --------
2015 2014 2015 2014
---- ---- ---- ----
(dollars in millions)
Cost of services $11 $11 $31 $23
Selling, general and
administrative 12 16 23 28
$23 $27 $54 $51
--- --- --- ---
(b) For the three months ended June 30,
2015, primarily represents a gain
of $13 million associated with a
decrease in the fair value of the
contingent consideration accrual
associated with our Summit Health
acquisition, partially offset by
costs incurred related to legal
matters and non-cash asset
impairment charges. For the six
month ended June 30, 2015,
primarily represents non-cash
asset impairment charges primarily
associated with our Celera
Products business and costs
incurred related to legal matters,
partially offset by a gain of $13
million associated with a decrease
in the fair value of the
contingent consideration accrual
associated with our Summit Health
acquisition.
For the three and six months ended
June 30, 2014, principally
represents costs incurred related
to the settlement of legal
matters.
(c) Charges on retirement of debt and
related refinancing charges
represent: charges associated with
the March 2015 cash tender offer
(the "Tender Offer") in which the
company purchased $250 million
aggregate principal amount of its
6.95% Senior Notes due July 2037
and 5.75% Senior Notes due January
2040; and charges associated with
the April 2015 redemption (the
"Redemption") in which the company
redeemed all of its 5.45% Senior
Notes due November 2015, $150
million of its 3.2% Senior Notes
due April 2016 and all of its 6.4%
Senior Notes due July 2017. The
following table summarizes the
impact of pre-tax charges on
retirement of debt and related
refinancing charges on the
company's consolidated statements
of operations:
Three Months Ended Six Months Ended
June 30, June 30,
-------- --------
2015 2014 2015 2014
---- ---- ---- ----
(dollars in millions)
Interest
expense, net $1 $ - $6 $ -
Other (expense)
income, net 65 - 144 -
$66 $ - $150 $ -
--- --- --- ---- --- ---
(d) For the charges on retirement of
debt and related refinancing
charges, income tax benefits
were calculated such that the
combined federal and state rate
for the full year will be 40%.
For the restructuring and
integration charges and other
items, income tax impacts,
where recorded, were calculated
using combined federal and
state rates of 38.9% and 38.2%
for 2015 and 2014,
respectively.
(e) Represents the impact of
amortization expense on diluted
earnings per common share, net
of the income tax benefit. The
income tax benefit was
calculated using combined
federal and state rates of
38.9% and 38.2% for 2015 and
2014, respectively.
(f) Represents $146 million of pre-
tax cash charges on retirement
of debt in connection with our
recent debt refinancing, net of
the estimated cash tax benefit.
3) Other operating (income) expense,
net includes miscellaneous income
and expense items related to
operating activities. For the
three months ended June 30, 2015,
other operating (income) expense,
net principally includes a gain of
$13 million associated with a
decrease in the fair value of the
contingent consideration accrual
associated with our Summit Health
acquisition, partially offset by a
non-cash asset impairment charge.
Other operating (income) expense,
net for the six months ended June
30, 2015, principally includes non-
cash asset impairment charges
primarily associated with our
Celera Products business,
substantially offset by a gain of
$13 million associated with a
decrease in the fair value of the
contingent consideration accrual
associated with our Summit Health
acquisition.
4) Other (expense) income, net
represents miscellaneous income and
expense items related to non-
operating activities, such as gains
and losses associated with
investments and other non-
operating assets. For the three
and six months ended June 30, 2015,
other (expense) income, net
includes $65 million and $144
million, respectively, of pre-tax
charges on the retirement of debt
associated with the Tender Offer
and Redemption.
5) For the three months ended June 30,
2015, the company repurchased 0.6
million shares of its common stock
at an average price of $72.03 per
share for $39 million. For the six
months ended June 30, 2015, the
company repurchased 2.1 million
shares of its common stock at an
average price of $71.62 per share
for $149 million. At June 30,
2015, $547 million remained
available under the company's share
repurchase authorizations.
6) The outlook for adjusted diluted EPS
excluding amortization expense
represents management's estimates
for the full year 2015 before the
impact of special items and
amortization expense. The outlook
for adjusted cash provided by
operations represents management's
estimate for the full year 2015
before the cash impact of charges
on retirement of debt. These
measures are presented because
management believes they are useful
adjuncts to the corresponding
amounts determined under accounting
principles generally accepted in
the United States since they are
meaningful to evaluate the
company's ongoing operating
performance. Adjusted diluted EPS
excluding amortization expense and
adjusted cash provided by
operations are not measures of
financial performance under
accounting principles generally
accepted in the United States and
should not be considered as
alternatives to the corresponding
amount determined under accounting
principles generally accepted in
the United States.
The following table reconciles our
2015 outlook for adjusted diluted
EPS excluding amortization expense
and adjusted cash provided by
operations to the corresponding
amounts determined under accounting
principles generally accepted in
the United States:
Low High
--- ----
Adjusted diluted EPS excluding
amortization expense:
Diluted earnings per common share $3.43 $3.58
Charges on retirement of debt and
related refinancing charges (a) 0.64 0.64
Restructuring and integration
charges (b) 0.22 0.22
Other (c) 0.04 0.04
Amortization expense, net of tax
(d) 0.37 0.37
---- ----
Adjusted diluted EPS excluding
amortization expense $4.70 $4.85
----- -----
Adjusted cash provided by
operations:
-------------------------
Cash provided by operations $723
Cash charges on retirement of debt
(e) 127
Adjusted cash provided by
operations $850
----
(a) Represents pre-tax charges of
$150 million, incurred through
June 30, 2015, associated with
the retirement of debt and
related refinancing charges in
connection with the Tender Offer
and Redemption.
(b) Represents pre-tax charges of $54
million primarily associated with
workforce reductions and
professional fees incurred in
connection with further
restructuring and integrating our
business through June 30, 2015.
(c) Represents pre-tax charges of $20
million associated with non-cash
impairment charges primarily
associated with our Celera
Products business and costs
incurred related to legal
matters, partially offset by a
gain of $13 million associated
with a decrease in the fair value
of the contingent consideration
accrual associated with our
Summit Health acquisition through
June 30, 2015.
(d) Represents the full year impact of
amortization expense (including
amortization expense associated
with our equity in earnings of
equity method investees),
estimated at approximately $88
million or $54 million, net of an
estimated tax benefit, on diluted
earnings per common share.
(e) Represents pre-tax cash charges
of $146 million on retirement of
debt in connection with our
recent debt refinancing, net of
the estimated cash tax benefit
through June 30, 2015.
7) The outlook for 2% to 3% revenue
growth represents management's
estimates for the full year 2015
versus reported full year 2014
revenues adjusted to exclude the
third and fourth quarter 2014
clinical trials revenue.
Effective July 1, 2015, the
company's clinical trials business
was contributed to the clinical
trials joint venture, consequently
our full year 2015 revenues will
not include these revenues in the
second half of 2015. Revenues for
2014 have been adjusted to exclude
clinical trials revenues to
provide an equivalent basis for
our growth outlook. The following
table reconciles our 2014 net
revenues determined under
accounting principles generally
accepted in the United States with
equivalent revenue for 2014:
2014 Net
Revenues
--------
2014 reported revenue $7,435
Excluded revenue (a) (87)
2014 equivalent revenue $7,348
------
2015 Revenue Outlook Low High
-------------------- --- ----
2014 equivalent revenue $7,348 $7,348
Growth outlook 2% 3%
2015 revenue outlook $7,490 $7,570
(a) The 2014 excluded revenue is
comprised of $41 million and
$46 million of clinical trials
revenues reported in the third
and fourth quarters of 2014,
respectively.
Contacts:
Dan Haemmerle (investors)
973-520-2900
Dennis Moynihan (media)
973-520-2800
Logo - http://photos.prnewswire.com/prnh/20150422/200883LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/quest-diagnostics-reports-second-quarter-2015-financial-results-300117535.html
SOURCE Quest Diagnostics Incorporated
